Literature DB >> 7648834

Validation of a modified Kirby-Bauer disk diffusion method for metronidazole susceptibility testing of Helicobacter pylori.

P D Midolo1, J Turnidge, J R Lambert, J M Bell.   

Abstract

Triple antimicrobial therapy that includes metronidazole has been recommended as a first-line therapy for Helicobacter pylori because it has the highest eradication rates. However, resistance in H. pylori to metronidazole has been reported worldwide and its presence may reduce the efficacy of triple therapy. Various methods for testing H. pylori against metronidazole have been used including agar dilution, disk diffusion and the Etest but there has been little standardization of methods. One hundred isolates of H. pylori from different patients were tested for susceptibility to metronidazole by agar dilution, Etest and disk diffusion (5 micrograms disk). The agar dilution results confirmed the MIC susceptibility breakpoint to be < or = 8 micrograms/ml. Using this breakpoint there was close agreement (98%) between Etest and agar dilution results. For susceptible strains, MICs by E-test were generally one twofold dilution lower. Using the error-rate bounded method, agreement between disk diffusion zone diameter and MIC was 98% for agar dilution with breakpoints of > or = 12 mm and < or = 8 micrograms/ml and 100% for Etest with breakpoints of > or = 12 mm and < or = 8 micrograms/ml. The Etest discriminated better than agar dilution between susceptible and resistant strains and was simple to perform. The disk diffusion test is a reliable and cheaper alternative to the Etest with susceptibility being a zone diameter > or = 12 mm with a 5 micrograms disk. The prevalence of metronidazole resistance in this study was 40% by Etest.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648834     DOI: 10.1016/0732-8893(95)00066-j

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran.

Authors:  Tahereh Falsafi; Fatemeh Mobasheri; Farahnaz Nariman; Mehri Najafi
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

2.  Helicobacter pylori antibiotic resistance in Iran.

Authors:  Marjan Mohammadi; Delaram Doroud; Nazanin Mohajerani; Sadegh Massarrat
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

3.  High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children.

Authors:  N Kalach; M Bergeret; P H Benhamou; C Dupont; J Raymond
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

4.  Subpopulations of Helicobacter pylori are responsible for discrepancies in the outcome of nitroimidazole susceptibility testing.

Authors:  E J van der Wouden; A de Jong; J C Thijs; J H Kleibeuker; A A van Zwet
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Assessment of metronidazole susceptibility in Helicobacter pylori: statistical validation and error rate analysis of breakpoints determined by the disk diffusion test.

Authors:  S Chaves; M Gadanho; R Tenreiro; J Cabrita
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

6.  Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children.

Authors:  J Raymond; N Kalach; M Bergeret; P H Benhamou; J P Barbet; D Gendrel; C Dupont
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands.

Authors:  E J van der Wouden; A A van Zwet; G D Vosmaer; J A Oom; A de Jong; J H Kleibeuker
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

8.  Moxifloxacin versus Clindamycin/Ceftriaxone in the management of odontogenic maxillofacial infectious processes: A preliminary, intrahospital, controlled clinical trial.

Authors:  Hansel Gómez-Arámbula; Antonio Hidalgo-Hurtado; Rosaura Rodríguez-Flores; Ana-María González-Amaro; Arturo Garrocho-Rangel; Amaury Pozos-Guillén
Journal:  J Clin Exp Dent       Date:  2015-12-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.